232 related articles for article (PubMed ID: 30411151)
1. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
[TBL] [Abstract][Full Text] [Related]
2. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
[TBL] [Abstract][Full Text] [Related]
4. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
[TBL] [Abstract][Full Text] [Related]
5. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM
Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
7. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
[TBL] [Abstract][Full Text] [Related]
8. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
9. Long-Term Effectiveness of the Zilver PTX Drug-Eluting Stent for Femoropopliteal Peripheral Artery Disease in Patients with No Patent Tibial Runoff Vessels-Results from the Zilver PTX Japan Post-Market Surveillance Study.
Cipollari S; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
J Vasc Interv Radiol; 2018 Jan; 29(1):9-17.e1. PubMed ID: 29122449
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
[TBL] [Abstract][Full Text] [Related]
11. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
12. Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents.
Soga Y; Fujihara M; Iida O; Kawasaki D; Hirano K; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Gray WA; Müller-Hülsbeck S
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):215-222. PubMed ID: 31690980
[TBL] [Abstract][Full Text] [Related]
13. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
14. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
[TBL] [Abstract][Full Text] [Related]
15. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
[TBL] [Abstract][Full Text] [Related]
16. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
[No Abstract] [Full Text] [Related]
17. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
Phillips JA; Falls A; Kolluri R; Whipp A; Collins C; Mohir-Sadaai S; Reid B; Patil N; Alston M; Troyan M; Ansel GM
J Endovasc Ther; 2018 Jun; 25(3):295-301. PubMed ID: 29544372
[TBL] [Abstract][Full Text] [Related]
18. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
Bosiers MJ; De Donato G; Torsello G; Silveira PG; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Eckstein HH; Teβarek J; Giaquinta A; van den Eynde W; Verbist J; Callaert J; Deloose K; Bosiers M
Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1348-1358. PubMed ID: 37670198
[TBL] [Abstract][Full Text] [Related]
19. ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis.
Bosiers M; DE Donato G; Torsello G; Galvagni Silveira P; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Tessarek J; Giaquinta A; van den Eynde W; Verbist J; Wahl-Gravsen J; Bosiers MJ
J Cardiovasc Surg (Torino); 2023 Aug; 64(4):413-421. PubMed ID: 37162238
[TBL] [Abstract][Full Text] [Related]
20. 24-Month Efficacy and Safety Results from Japanese Patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent.
Iida O; Fujihara M; Kawasaki D; Mori S; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Müller-Hülsbeck S; Gray WA; Soga Y
Cardiovasc Intervent Radiol; 2021 Sep; 44(9):1367-1374. PubMed ID: 34235560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
